Precision medicine and data
Prenosis Sepsis ImmunoScore
FDA De Novo-authorized AI/ML software that assigns adult emergency department or hospital patients to sepsis risk categories within a clinician-reviewed workflow.
Last updated: June 5, 2026
Back to directoryOwkin K Pro medical AI product profile
Biology-focused AI agent platform for drug discovery and development workflows using multimodal patient data and specialized biomedical AI skills.
Precision medicine and data
Best fit
Research teams that need governed analysis across genomic, transcriptomic, spatial, clinical, and literature data for discovery or biomarker work.
- Primary use case
- Agentic AI for biomedical research, multimodal patient data analysis, target prioritization, biomarker validation, and drug-development decisions
- Audience
- Biopharma R&D teams, translational medicine groups, computational biology teams, and precision-oncology researchers
- Risk level
- High
- Pricing signal
- Enterprise and partner pricing; verify current access and deployment terms.
- Official sources
- 3 official sources
Compare within workflow: Precision medicine and data · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Owkin K Pro as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat K Pro as biomedical research and drug-development support unless a deployment links outputs to patient-specific care or regulated-development decisions that need formal controls. |
|---|---|
| Privacy | Confirm whether data enters Owkin K, a customer environment, or the patient-data network, then review GDPR, ISO, data-transfer, de-identification, and access-control terms. |
| Evidence | Require visible source data, reproducible methods, statistical assumptions, uncertainty, and expert review for target, biomarker, subgroup, or report-generation claims. |
| Workflow | Best used inside governed R&D workflows where domain scientists review generated analyses before they influence experiments, trial design, or translational strategy. |
Where Owkin K Pro fits
Owkin describes K Pro as an AI agent for biology that uses multimodal patient data and specialized AI skills for drug discovery and development tasks such as target prioritization, patient subgroup characterization, biomarker validation, and statistical report generation.
Not for: Point-of-care clinical decisions, unsupervised patient diagnosis, or treatment recommendations outside validated research and review workflows.
What to verify before using Owkin K Pro
- Which datasets, AI skills, and biomedical tasks are available for the research question.
- Whether the deployment model, ISO27001/GDPR controls, and data integration terms match institutional policy.
- How generated analyses cite data sources, statistical methods, uncertainty, and reproducibility artifacts.
- Whether outputs are reviewed by domain experts before influencing trials, biomarkers, or clinical strategy.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- www.owkin.com / k-os / k-pro
- docs.owkin.com / user-guide / getting-started
- www.owkin.com / patient-data-network
Related medical AI products
Precision medicine and data
Anumana ECG-AI
Cardiovascular AI platform using standard 12-lead ECGs to surface signals such as low ejection fraction, pulmonary hypertension, and cardiac amyloidosis for clinician follow-up.
Precision medicine and data
Eko Health SENSORA
FDA-cleared cardiovascular detection platform that pairs Eko digital stethoscopes with AI-supported ECG and heart-sound analysis for supervised point-of-care screening.
Precision medicine and data
AliveCor Kardia 12L
Portable AI-powered 12-lead ECG system that uses a reduced leadset and KAI 12L algorithms to support clinician-reviewed cardiac determinations.